BOSTON SCIENTIFIC CORP

NYSE: BSX (Boston Scientific Corporation)

Last update: 3 days ago, 7:40PM

107.22

-0.07 (-0.07%)

Previous Close 107.29
Open 107.11
Volume 4,062,435
Avg. Volume (3M) 7,206,740
Market Cap 158,873,239,552
Price / Earnings (TTM) 63.82
Price / Earnings (Forward) 35.46
Price / Sales 8.51
Price / Book 6.97
52 Weeks Range
80.64 (-24%) — 108.94 (1%)
Earnings Date 22 Oct 2025
Profit Margin 11.58%
Operating Margin (TTM) 20.09%
Diluted EPS (TTM) 1.37
Quarterly Revenue Growth (YOY) 20.90%
Quarterly Earnings Growth (YOY) 36.20%
Total Debt/Equity (MRQ) 52.16%
Current Ratio (MRQ) 1.45
Operating Cash Flow (TTM) 3.81 B
Levered Free Cash Flow (TTM) 2.32 B
Return on Assets (TTM) 5.28%
Return on Equity (TTM) 9.50%

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Bearish Bearish
Medical Devices (Global) Bearish Bearish
Stock Boston Scientific Corporation Bullish Bullish

AIStockmoo Score

1.4
Analyst Consensus 4.0
Insider Activity -3.0
Price Volatility -0.5
Technical Moving Averages 2.5
Technical Oscillators 4.0
Average 1.40

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
BSX 159 B - 63.82 6.97
SYK 147 B 0.64% 51.04 7.09
PHG 26 B - 145.16 2.19
ABT 232 B 0.85% 17.33 4.58
MDT 113 B 2.37% 24.27 2.49
EW 46 B - 32.20 4.47

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Sector Healthcare
Industry Medical Devices
Investment Style Large Core
% Held by Insiders 0.18%
% Held by Institutions 93.22%

Ownership

Name Date Shares Held
Bollard Group Llc 30 Jun 2025 20,079,443
52 Weeks Range
80.64 (-24%) — 108.94 (1%)
Price Target Range
118.00 (10%) — 135.00 (25%)
High 135.00 (UBS, 25.91%) Buy
Median 124.50 (16.12%)
Low 118.00 (Leerink Partners, 10.05%) Buy
Average 125.88 (17.40%)
Total 8 Buy
Avg. Price @ Call 105.75
Firm Date Target Price Call Price @ Call
Oppenheimer 08 Sep 2025 125.00 (16.58%) Buy 107.22
24 Jul 2025 118.00 (10.05%) Hold 106.21
Baird 24 Jul 2025 123.00 (14.72%) Buy 106.21
Barclays 24 Jul 2025 133.00 (24.04%) Buy 106.21
Raymond James 24 Jul 2025 124.00 (15.65%) Buy 106.21
Truist Securities 24 Jul 2025 125.00 (16.58%) Buy 106.21
UBS 24 Jul 2025 135.00 (25.91%) Buy 106.21
Wells Fargo 24 Jul 2025 124.00 (15.65%) Buy 106.21
Leerink Partners 16 Jun 2025 118.00 (10.05%) Buy 101.49
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
FITZGERALD JOSEPH MICHAEL - 106.66 -50,000 -5,333,000
Aggregate Net Quantity -50,000
Aggregate Net Value ($) -5,333,000
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 106.66
Name Holder Date Type Quantity Price Value ($)
FITZGERALD JOSEPH MICHAEL Officer 02 Sep 2025 Automatic sell (-) 50,000 106.66 5,333,000
FITZGERALD JOSEPH MICHAEL Officer 02 Sep 2025 Option execute 50,000 - -

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria